NEW YORK, May 21 (Reuters) - Cigna CI.N said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more than $200 a month out-of-pocket for weight-loss drugs Wegovy and Zepbound.
Cigna's pricing compares to the cash-pay market for weight-loss drugs, said Harold Carter, a senior vice president at Evernorth.
(Reporting by Amina Niasse; editing by Caroline Humer)
((amina.niasse@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。